To access the full text documents, please follow this link: http://hdl.handle.net/11351/5846
dc.contributor | Institut Català de la Salut |
---|---|
dc.contributor | [Lopez-Bonet E] Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona 17005, Spain. [Buxó M] Girona Biomedical Research Institute (IDIBGI), Girona 17190, Spain. [Cuyàs E] Girona Biomedical Research Institute (IDIBGI), Girona 17190, Spain. Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona 08908, Spain. [Pernas S] Department of Medical Oncology, Breast Unit, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona 08908, Spain. [Dorca J] Medical Oncology, Catalan Institute of Oncology, Girona 17005, Spain. [Álvarez I] Medical Oncology Service, Hospital Universitario Donostia, Donostia-San Sebastián 20014, Spain. Biodonostia Health Research Institute, Donostia-San Sebastián 20014, Spain. [Cortés J] IOB Institute of Oncology, Hospital Quirónsalud, Madrid & Barcelona 08023, Spain. Medica Scientia Innovation Researcher (MedSIR), Barcelona 08007, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.contributor | Hospital Universitari Vall d'Hebron |
dc.contributor.author | Lopez-Bonet, Eugeni |
dc.contributor.author | Buxó, Maria |
dc.contributor.author | Cuyàs, Elisabet |
dc.contributor.author | Pernas, Sonia |
dc.contributor.author | Dorca, Joan |
dc.contributor.author | Álvarez, Isabel |
dc.contributor.author | Cortés Castan, Javier |
dc.date | 2021-04-13T14:08:29Z |
dc.date | 2021-04-13T14:08:29Z |
dc.date | 2019-12-11 |
dc.identifier | Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, et al. Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. J Clin Med. 2019 Dec 11;8(12):2180. |
dc.identifier | 2077-0383 |
dc.identifier | http://hdl.handle.net/11351/5846 |
dc.identifier | 10.3390/jcm8122180 |
dc.identifier | 31835708 |
dc.identifier | 000506640400150 |
dc.identifier.uri | http://hdl.handle.net/11351/5846 |
dc.format | application/pdf |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | MDPI |
dc.relation | Journal of Clinical Medicine;8(12) |
dc.relation | https://www.mdpi.com/2077-0383/8/12/2180 |
dc.relation | info:eu-repo/grantAgreement/ES/PE2013-2016/SAF2016-80639-P |
dc.rights | Attribution 4.0 International |
dc.rights | http://creativecommons.org/licenses/by/4.0/ |
dc.rights | info:eu-repo/semantics/openAccess |
dc.source | Scientia |
dc.subject | Metformina |
dc.subject | Mama - Càncer |
dc.subject | DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms |
dc.subject | Other subheadings::Other subheadings::Other subheadings::/drug therapy |
dc.subject | ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama |
dc.subject | Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia |
dc.title | Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |
dc.description.abstract | |
dc.description.abstract | |
dc.description.abstract | |
dc.description.abstract | |
dc.description.abstract |